$18.28
2.64% yesterday
Nasdaq, Jul 17, 10:04 pm CET
ISIN
US45258J1025
Symbol
IMVT

Immunovant Inc Stock price

$18.28
+2.97 19.40% 1M
-5.58 23.39% 6M
-6.49 26.20% YTD
-11.70 39.03% 1Y
+14.22 350.25% 3Y
-6.05 24.87% 5Y
+8.33 83.72% 10Y
+8.33 83.72% 20Y
Nasdaq, Closing price Thu, Jul 17 2025
+0.47 2.64%
ISIN
US45258J1025
Symbol
IMVT
Sector

Key metrics

Basic
Market capitalization
$3.1b
Enterprise Value
$2.4b
Net debt
positive
Cash
$714.0m
Shares outstanding
170.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
4.4
Financial Health
Equity Ratio
91.1%
Return on Equity
-58.5%
ROCE
-61.9%
ROIC
-990.7%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-437.8m | $-518.9m
EBIT
$-438.2m | $-411.3m
Net Income
$-413.8m | $-503.8m
Free Cash Flow
$-376.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-62.1% | -18.5%
EBIT
-62.2% | 6.1%
Net Income
-59.6% | -21.7%
Free Cash Flow
-75.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.5
FCF per Share
$-2.2
Short interest
22.5%
Employees
207
Rev per Employee
$0.0
Show more

Is Immunovant Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,004 stocks worldwide.

Immunovant Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

21 Analysts have issued a Immunovant Inc forecast:

17x Buy
81%
4x Hold
19%

Analyst Opinions

21 Analysts have issued a Immunovant Inc forecast:

Buy
81%
Hold
19%

Financial data from Immunovant Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 77 77
35% 35%
-
- Research and Development Expense 361 361
70% 70%
-
-438 -438
62% 62%
-
- Depreciation and Amortization 0.38 0.38
65% 65%
-
EBIT (Operating Income) EBIT -438 -438
62% 62%
-
Net Profit -414 -414
60% 60%
-

In millions USD.

Don't miss a Thing! We will send you all news about Immunovant Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Immunovant Inc Stock News

Neutral
GlobeNewsWire
about 2 months ago
Immunovant's new management team is focused on rapid clinical execution for the six announced indications for IMVT-1402, including a second potentially registrational study in Graves' disease (GD) and a potentially registrational study in Sjögren's disease (SjD), both expected to start in summer 2025 Positive data from first-generation batoclimab trials in myasthenia gravis (MG) and chronic inf...
Neutral
Business Wire
about 2 months ago
SAN DIEGO--(BUSINESS WIRE)--Robbins Geller Rudman & Dowd LLP announces an investigation into potential breaches of fiduciary duty by the directors and officers of Immunovant, Inc. (NASDAQ: IMVT) and Roivant Sciences Ltd. – Immunovant's controlling stockholder – in connection with Immunovant's January 2025 private placement transaction in which Roivant purchased nearly 16.9 million Immunovant sh...
Negative
Investors Business Daily
3 months ago
Roivant Sciences is making serious changes to subsidiary Immunovant, announcing Monday a series of C-suite changes and new disease targets.
More Immunovant Inc News

Company Profile

Immunovant, Inc. is a clinical-stage biopharmaceutical company. It focuses on enabling normal lives for patients with autoimmune diseases. The company was founded in 2018 and is headquartered in New York, NY.

Head office United States
CEO Eric Venker
Employees 207
Founded 2018
Website immunovant.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today